Cancer-Killing viruses take on solid tumours in new trial

NCT ID NCT02285816

Ongoing Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 1/2 trial tests a vaccine made from two viruses designed to target and kill cancer cells that have a specific protein called MAGE-A3. The viruses are given to 56 people with advanced solid tumours that have not responded to other treatments. The goal is to see if the vaccine can shrink tumours and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MG1 Maraba/MAGE-A3 virus vaccine (with or without adenovirus priming)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumours that express the MAGE-A3 protein, potentially shrinking tumours and extending life.
What could go wrong: This is an early-phase trial with only 56 participants, so results may not apply to everyone. The treatment may cause side effects or fail to shrink tumours, and it is not yet clear if it works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMOURS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer esophageal cancer gastric cancer gastroesophageal junction adenocarcinoma metastatic malignant neoplasm metastatic neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED/METASTATIC SOLID TUMOURS

Contacts and locations

Locations

BCCA - Vancouver Cancer Centre

Vancouver, British Columbia, V5Z 4E6, Canada
Juravinski Cancer Centre at Hamilton Health Sciences

Hamilton, Ontario, L8V 5C2, Canada
Ottawa Hospital Research Institute

Ottawa, Ontario, K1H 8L6, Canada
University Health Network

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.